Bria-OVA+ / BriaCell - LARVOL DELTA

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+ (GlobeNewswire) - "Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity....BriaCell believes...multipronged immune activation supports the potential of the Bria-OTS+ platform to generate anti-tumor immune responses and may help inform the development of Bria-OVA+ for ovarian cancer."

Pipeline update • Ovarian Cancer